16 results about "Nasal Drops" patented technology

1. Name of the designed product: medicine packing bottle (purple nose gel nasal drops). 2. Use of the designed product: for packing of purple nose gel nasal drops. 3. Design points of the designed product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The invention discloses a method for constructing a Yunnan pine pollen allergy animal model, which belongs to the technical field of Yunnan pine pollen allergy prevention and treatment and comprises the following steps: preparing Yunnan pine pollen allergens and sensitizing non-human mammals. The sensitization treatment comprises a basic sensitization treatment stage and an excitation sensitization treatment stage: in the basic sensitization treatment stage, peritoneal sensitization is carried out once a week and is continued for four weeks; in the nasal-drop sensitization treatment stage, different test substances with the concentration 2 times that of the basic sensitization stage are used for continuous 7-day quantitative nasal-drop excitation, and the nasal drop dosage is 2 microliters / g, and the symptoms of the mouse are observed within 10 minutes after nasal-drop excitation is completed each time. The allergic animal model constructed by adopting the crude extract of the pinus yunnanensis pollen allergen is the first animal model research related to pinus yunnanensis allergy at present, and a reference basis can be provided for subsequent experimental research on the aspect of deep research on pinus yunnanensis pollen allergy; a research model is provided for clinical research on the Yunnan pine pollen allergy or screening of medicines for resisting the Yunnan pine pollen allergy.

The invention discloses a mouse BHDS pulmonary focal degenerative pulmonary bullous model construction method and application, and the method comprises the following steps: adaptively feeding a healthy mouse for one week, then carrying out HCl injury treatment, and giving two microRNA fitting substances to the mouse twice in a nasal drop mode to obtain the BHDS pulmonary focal degenerative pulmonary bullous model. Expression changes of characteristic molecules in BHDS clinical sample lung tissues exist in the lung tissues of the model constructed by the invention, and the model is most suitable for BHDS-like lung tissue pathology so far. The invention provides a proper tool model for the effectiveness, safety and drug screening of BHDS pulmonary focal degenerative pulmonary bullous (BHD syndrome pulmonary cystic disease) treatment drugs, and ensures the repeatability and high efficiency of the model. Compared with a model constructed by gene knockout, the construction method provided by the invention is more stable in model formation, simpler and more convenient in operation method and experimental technology, and lower in cost.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

The invention discloses an akabane virus challenge animal model and an establishment method and application thereof, and belongs to the technical field of animal models.According to the establishment method, a BALB / c mouse or a C57BL / 6N mouse is challenged in a nasal drop mode, so that an akabane virus challenge BALB / c mouse model or an akabane virus challenge C57BL / 6N mouse model is obtained, akabane virus liquid is adopted in the nasal drop mode, and the akabane virus liquid is adopted in the nasal drop mode. The akabane virus liquid is obtained from akabane viruses in an in-vitro cell culture mode, and the akabane virus strains are preferably GXLCH 16-70 strains; the akabane virus counteracting animal model constructed by adopting the method disclosed by the invention expands the universality of the akabane virus counteracting model on the week age and strain of the mouse, and is particularly applicable to model construction of the mouse with mature immune system; the obtained model has great application prospects in evaluating the effectiveness of akabane virus vaccines, screening akabane disease prevention drugs or screening akabane disease treatment drugs.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention relates to an engineered mesenchymal stem cell exosome complex, comprising mesenchymal stem cell exosomes and siRNA loaded on the mesenchymal stem cell exosomes. The invention also relates to a nasal drop formulation comprising the aforementioned exosome complex, which can be used to prepare a drug for treating bronchopulmonary dysplasia. The complex and formulation of the present invention possess unique advantages such as enhanced therapeutic specificity through targeted gene silencing, stable pulmonary vascular pathological repair effects, and engineered targeted therapy.

The application discloses a kind of nasal drops based on drug-loaded pollen for rhinitis and its preparation method and application, belong to the field of biomedical materials;The nasal drops include drug-loaded pollen microcarrier and pharmaceutically acceptable adjuvant;The drug-loaded pollen microcarrier is natural sunflower pollen particle with hollow cavity and surface thorn structure, and the cavity is loaded with the drug for treating allergic rhinitis.In the preparation method, sunflower pollen is washed, defatted with acetone diethyl ether, and treated with phosphoric acid cleavage to obtain pollen microcarrier with hollow outer thorn;Then, small molecule drugs are loaded under vacuum and reduced pressure;Finally, the adjuvant is mixed to prepare the drops.The application utilizes the natural "internal cavity and external thorn" structure of pollen, realizes efficient adhesion and sustained-release drug delivery in nasal cavity, and effectively resists cilia clearance.The pollen microcarrier removes allergenic proteins, has good biocompatibility, and does not aggravate allergic rhinitis.The application is low in cost and simple in operation, and provides a safe and efficient new platform for nasal drug delivery.

This invention provides a poultry immunization device, comprising a body, a clamping unit and an eye / nasal drop unit disposed on one side of the bottom of the body, and an injection unit disposed on the other side of the bottom of the body. The injection unit is connected to the clamping unit and the eye / nasal drop unit via pipes. Protective shielding units are disposed on the surfaces of the clamping unit and the eye / nasal drop unit. A buffer storage compartment is disposed at the bottom of the clamping unit and the eye / nasal drop unit to temporarily store the immunized poultry. A control unit is disposed at the top of the body, and the control unit is signal-connected to the clamping unit, the injection unit, and the eye / nasal drop unit. The clamping unit facilitates operation, ensures accurate immunization injection, and provides a suitable clamping position for the poultry. Furthermore, it ensures high operational safety, as the poultry automatically moves up and down after being clamped, avoiding the risk of accidental injury to the operator.

The embodiment of the application discloses a method for constructing a human respiratory syncytial virus newborn mouse infection model and application thereof.The method comprises the following steps: inoculating a virus liquid containing a human respiratory syncytial virus (RSV) into a 3-day-old SPF healthy BALB / c newborn mouse through nasal drops, and obtaining the human respiratory syncytial virus newborn mouse infection model after 4-5 days.The application successfully establishes a newborn mouse infection model which is simple to operate, good in repeatability and closer to clinical pathological characteristics.The model has the advantages of high virus infection rate, high similarity of pathological characteristics to human newborn infection, simple model construction method, short cycle, low cost, good stability and strong repeatability, and has a wide application prospect in RSV related research and development.

The application discloses a preparation method of a nasal drop with traditional Chinese medicine biological components for treating rhinitis, and comprises the following steps: step one, preparing the first type of nasal drop: frying Semen Xanthii is matched with Magnolia and Bai Zhi to prepare the first type of nasal drop; step two, preparing the second type of nasal drop: using Mentha with Chrysanthemum and Forsythia to prepare the second type of nasal drop; step three, preparing the third type of nasal drop: matching Huangqi with Baishu and Fangfeng to prepare the second type of nasal drop; step four, preparing the finished product: mixing the prepared first type of nasal drop, the second type of nasal drop and the third type of nasal drop to obtain the finished product, wherein the raw materials of the nasal drop are all traditional Chinese medicines, the traditional Chinese medicine preparation has the characteristics of safety and reliability, easy purchase of raw materials, moderate price and easy production, and the traditional Chinese medicine preparation has the characteristics of broad-spectrum treatment of rhinitis, replacement of traditional hormone treatment, reduction of damage of the medicine to the human body and high safety.

This invention relates to the field of traditional Chinese medicine antibacterial liquid technology, and particularly to a traditional Chinese medicine antibacterial liquid for nasal use, made from the following raw materials: Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, Mentha haplocalyx, and polyhexamethylene biguanide. This invention combines nine traditional Chinese medicines—Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, and Mentha haplocalyx—with polyhexamethylene biguanide. The traditional Chinese medicine components are an improvement on the ancient formula of Xanthium sibiricum powder, synergistically exerting the effects of clearing the lungs and nasal passages, dispelling wind and cold, and anti-inflammatory and anti-allergic properties. Polyhexamethylene biguanide provides broad-spectrum antibacterial efficacy. By changing the traditional oral dosage form to a nasal drop, the liquid acts directly on the nasal mucosa lesion site, avoiding the first-pass effect of the liver and the metabolic burden on the kidneys associated with oral medications, significantly improving drug safety. Skin irritation, eye irritation, and allergy tests all showed no irritation or sensitization.

This invention provides a subunit vaccine containing Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant. The subunit vaccine comprises the Mycoplasma pneumoniae HP14 / 30 fusion antigen and a mucosal adjuvant in a mass ratio of 1-5:1. The HP14 / 30 fusion antigen is a recombinant protein co-expressed by chimeric fragments of the P1 and P30 proteins, with the amino acid sequence shown in SEQ ID NO:1. This vaccine is administered via mucosal routes such as nasal drops or oral inhalation. It efficiently induces respiratory mucosal-specific IgA and humoral IgG responses, significantly reduces pathogen load in the lungs, alleviates pathological damage to lung tissue, and does not induce enhanced respiratory disease (ERD). Its safety and protective efficacy are significantly superior to traditional inactivated vaccines and intramuscular vaccines. This invention fills the technological gap in human Mycoplasma pneumoniae subunit vaccines, is suitable for the prevention of Mycoplasma pneumoniae infection in children and adults, and has significant clinical application value.

The invention discloses a nasal preparation prepared from penehyclidine hydrochloride and application of the nasal preparation in treatment of rhinitis diseases. The upper respiratory tract is infected by bacteria and viruses or stimulated by foreign matters (such as pollen, hair, dust, cold air and the like), so that clinical symptoms such as sneezing, nasal obstruction, running nose and the like occur in the nasal cavity, namely acute rhinitis or chronic rhinitis diseases are caused. The medicine for treating the rhinitis disease is a medicine preparation such as nose drops, spray and the like prepared by taking a penehyclidine hydrochloride compound as a main component and adding pharmaceutically acceptable auxiliary components, the administration route is nasal local administration, and the weight-volume ratio of penehyclidine hydrochloride to the auxiliary components is (1: 250)-(1: 10000). The application field of the penehyclidine hydrochloride compound is widened, a novel medicine is provided for specific people with rhinitis symptoms, and the novel medicine adopts local administration and has the advantages that active ingredients directly reach focus parts, the medicine takes effect quickly, the local bioavailability is high, the duration time is long, the dosage is small, and the occurrence rate of adverse reactions is greatly reduced.

A physiologically-active peptide derivative for treatment of an eye disease, the physiologically-active peptide derivative having a physiologically-active peptide sequence and a functional sequence, and the functional sequence including a cell-penetration accelerating sequence and an endosomal-escape accelerating sequence.